Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-B7-H3 Antibody-FITC (7G630) is a FITC-conjugated Mouse antibody targeting B7-H3. Anti-B7-H3 Antibody-FITC (7G630) can be used in FCM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 T | $82 | 7-10 days | |
100 T | $258 | 7-10 days |
Description | Anti-B7-H3 Antibody-FITC (7G630) is a FITC-conjugated Mouse antibody targeting B7-H3. Anti-B7-H3 Antibody-FITC (7G630) can be used in FCM. |
Alias | CD276 molecule, B7RP-2, B7-H3, B7H3, 4Ig-B7-H3 |
Ig Type | Monoclonal Mouse IgG2b |
Clone | 7G630 |
Reactivity | Human |
Verified Activity | Flow cytometric analysis of anti-B7H3 (CD276) reactivity on PC-3 cells. |
Application | FCM |
Recommended Dose | 10 μl/Test, 0.1 mg/ml |
Antibody Type | Monoclonal |
Host Species | Mouse |
Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human B7-H3 / CD276 (rh B7-H3 / CD276; TMPY-02031; Q5ZPR3-1; Met 1-Thr 461) and conjugated with FITC under optimum conditions, the unreacted FITC was removed. |
Purification | Protein A |
Appearance | Liquid |
Formulation | PBS solution containing 0.5% BSA and 0.03%ProClin300 |
Research Background | B7-H3 is a member of the B7 family of immune regulatory ligands that is thought to attenuate peripheral immune responses through co-inhibition. It plays an important role in adaptive immune responses, and was shown to either promote or inhibit T-cell responses in various experimental systems. B7-H3 may play an important role in muscle-immune interactions, providing further evidence of the active role of muscle cells in local immunoregulatory processes. B7-H3 is a novel protein structurally related to the B7 family of ligands by the presence of a single set of immunoglobulin-V-like and immunoglobulin-C-like (VC) domains. Previous studies have correlated its overexpression with poor prognosis and decreased tumor-infiltrating lymphocytes in various carcinomas including uterine endometrioid carcinomas, and mounting evidence supports an immuno-inhibitory role in ovarian cancer prognosis. Recently, B7-H3 expression has been reported in several human cancers indicating an additional function of B7-H3 as a regulator of antitumor immunity.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: ICC AntibodiesImmune Checkpoint Detection: IP AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
Conjucates | FITC |
Others Formats | Unconjugated/APC/HRP/PE |
Antibody Types Available | 5 |
Immunogen | Recombinant Human B7-H3 / CD276 protein (TMPY-02031) |
Antigen Species | Human |
Biology Area | Cancer Drug Targets |
Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.